Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
作者信息
Pollock Richard F, Muduma Gorden
机构信息
Covalence Research Ltd, London, UK.
Pharmacosmos A/S, Holbaek, Denmark.
出版信息
Adv Ther. 2019 Aug;36(8):1821-1825. doi: 10.1007/s12325-019-00993-8. Epub 2019 Jun 1.
Abstract
摘要
相似文献
1
Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.回应：丹麦炎性肠病合并缺铁性贫血患者中异麦芽糖酐铁1000与羧基麦芽糖铁的经济学评价
Adv Ther. 2019 Aug;36(8):1821-1825. doi: 10.1007/s12325-019-00993-8. Epub 2019 Jun 1.
2
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.信函：丹麦炎症性肠病合并缺铁性贫血患者中异麦芽糖酐铁1000与羧基麦芽糖铁的经济学评价
Adv Ther. 2019 Aug;36(8):1817-1820. doi: 10.1007/s12325-019-00990-x. Epub 2019 Jun 1.
3
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.丹麦炎性肠病伴缺铁性贫血患者用异麦芽糖铁 1000 与羧基麦芽糖铁进行经济学评价。
Adv Ther. 2018 Dec;35(12):2128-2137. doi: 10.1007/s12325-018-0827-5. Epub 2018 Nov 19.
4
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.铁羧基麦芽糖铁或葡萄糖酸亚铁治疗炎症性肠病患者的低磷血症发生率。
Aliment Pharmacol Ther. 2019 Aug;50(4):397-406. doi: 10.1111/apt.15386. Epub 2019 Jul 2.
5
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.在英国，炎症性肠病伴缺铁性贫血患者中，去铁麦芽糖铁与羧基麦芽糖铁的成本-效用分析。
J Med Econ. 2024 Jan-Dec;27(1):392-403. doi: 10.1080/13696998.2024.2313932. Epub 2024 Mar 11.
6
A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.一项针对英国缺铁性贫血治疗中铁异麦芽糖与羧基麦芽糖铁的患者水平成本效益分析。
J Med Econ. 2020 Jul;23(7):751-759. doi: 10.1080/13696998.2020.1745535. Epub 2020 May 1.
7
Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer ) versus ferric carboxy-maltose (Ferinject ). A single center, cohort study.静脉铁剂过敏反应的比较：异麦芽糖铁 1000（Monofer）与羧基麦芽糖铁（Ferinject）。单中心、队列研究。
Br J Clin Pharmacol. 2019 Feb;85(2):385-392. doi: 10.1111/bcp.13805. Epub 2018 Dec 11.
8
Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.静脉铁剂治疗炎症性肠病缺铁性贫血：英国异麦芽糖酐 1000（Monofer）治疗缺铁性贫血的预算影响分析。
Expert Opin Drug Deliv. 2017 Dec;14(12):1439-1446. doi: 10.1080/17425247.2017.1393412. Epub 2017 Oct 24.
9
The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.静脉铁治疗在 IBD 患者中的医疗费用取决于经济评价视角。
J Crohns Colitis. 2010 Oct;4(4):427-30. doi: 10.1016/j.crohns.2010.01.007. Epub 2010 Feb 16.
10
Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.炎症性肠病缺铁患者单次输注英夫利昔单抗后立即使用羧基麦芽糖铁的安全性：一项初步研究。
PLoS One. 2015 May 26;10(5):e0128156. doi: 10.1371/journal.pone.0128156. eCollection 2015.
引用本文的文献
1
Economic Analysis of Intravenous Iron in Patients with Iron Deficiency Anemia Due to Inflammatory Bowel Disease: Considerations for Clinicians [Letter].炎症性肠病所致缺铁性贫血患者静脉补铁的经济学分析：临床医生需考虑的因素[信函]
Clinicoecon Outcomes Res. 2022 Apr 4;14:163-165. doi: 10.2147/CEOR.S363642. eCollection 2022.
本文引用的文献
1
An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease.炎症性肠病缺铁性贫血的评估与管理最新进展
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):95-97. doi: 10.1080/17474124.2019.1553618. Epub 2018 Dec 7.
2
A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.一项口服铁治疗失败或不耐受后铁缺乏性贫血中铁异麦芽糖和羧基麦芽糖铁的系统文献回顾和间接比较。
Expert Rev Hematol. 2019 Feb;12(2):129-136. doi: 10.1080/17474086.2019.1575202. Epub 2019 Feb 19.
3
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.丹麦炎性肠病伴缺铁性贫血患者用异麦芽糖铁 1000 与羧基麦芽糖铁进行经济学评价。
Adv Ther. 2018 Dec;35(12):2128-2137. doi: 10.1007/s12325-018-0827-5. Epub 2018 Nov 19.
4
Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.静脉铁剂治疗炎症性肠病缺铁性贫血：英国异麦芽糖酐 1000（Monofer）治疗缺铁性贫血的预算影响分析。
Expert Opin Drug Deliv. 2017 Dec;14(12):1439-1446. doi: 10.1080/17425247.2017.1393412. Epub 2017 Oct 24.
5
Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies-authors' reply.信函：确定静脉铁剂治疗的相对疗效时给药剂量和基线血红蛋白的重要性——作者回复
Aliment Pharmacol Ther. 2017 Oct;46(7):705-706. doi: 10.1111/apt.14269.
6
Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.系统评价与网络荟萃分析：比较不同静脉用铁剂治疗炎症性肠病患者缺铁性贫血的疗效和耐受性。
Aliment Pharmacol Ther. 2017 May;45(10):1303-1318. doi: 10.1111/apt.14043. Epub 2017 Mar 21.
7
Safety of intravenous iron use in chronic kidney disease.慢性肾脏病患者静脉补铁的安全性
Curr Opin Nephrol Hypertens. 2016 Nov;25(6):529-535. doi: 10.1097/MNH.0000000000000263.
8
High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.高剂量快速输注异麦芽糖酐铁对缺铁性贫血的炎症性肠病患者有效，且不会使磷酸盐或成纤维细胞生长因子23发生显著变化。
Scand J Gastroenterol. 2016 Nov;51(11):1332-8. doi: 10.1080/00365521.2016.1196496. Epub 2016 Jun 21.
9
European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.欧洲关于炎症性肠病中铁缺乏症和贫血症诊断与管理的共识
J Crohns Colitis. 2015 Mar;9(3):211-22. doi: 10.1093/ecco-jcc/jju009. Epub 2014 Dec 3.
10
A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).一项比较静脉注射异麦芽糖铁 1000 治疗（Monofer）与口服铁剂治疗 IBD 贫血的随机、开放标签、非劣效性研究（PROCEED）。
Am J Gastroenterol. 2013 Dec;108(12):1877-88. doi: 10.1038/ajg.2013.335. Epub 2013 Oct 22.
Zotero 插件